[go: up one dir, main page]

MA28579B1 - Dérivés de tétrahydronaphtyridine utiles comme ligands du récepteur d'histamine H3 - Google Patents

Dérivés de tétrahydronaphtyridine utiles comme ligands du récepteur d'histamine H3

Info

Publication number
MA28579B1
MA28579B1 MA29447A MA29447A MA28579B1 MA 28579 B1 MA28579 B1 MA 28579B1 MA 29447 A MA29447 A MA 29447A MA 29447 A MA29447 A MA 29447A MA 28579 B1 MA28579 B1 MA 28579B1
Authority
MA
Morocco
Prior art keywords
histamine
receptor ligands
derivatives useful
tetrahydronaphthyridine derivatives
tetrahydronaphthyridine
Prior art date
Application number
MA29447A
Other languages
English (en)
Inventor
Graham Lunn
John Paul Mathias
Ross Sinclair Strang
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MA28579B1 publication Critical patent/MA28579B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
MA29447A 2004-05-12 2006-11-10 Dérivés de tétrahydronaphtyridine utiles comme ligands du récepteur d'histamine H3 MA28579B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04291222A EP1595881A1 (fr) 2004-05-12 2004-05-12 Dérivés de tetrahydronaphthyridine en tant que ligands de récepteur H3 d'histamine

Publications (1)

Publication Number Publication Date
MA28579B1 true MA28579B1 (fr) 2007-05-02

Family

ID=34931096

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29447A MA28579B1 (fr) 2004-05-12 2006-11-10 Dérivés de tétrahydronaphtyridine utiles comme ligands du récepteur d'histamine H3

Country Status (32)

Country Link
US (2) US7557121B2 (fr)
EP (2) EP1595881A1 (fr)
JP (1) JP4084410B2 (fr)
KR (1) KR100908155B1 (fr)
CN (2) CN1950371B (fr)
AP (1) AP2006003786A0 (fr)
AR (1) AR049092A1 (fr)
AT (1) ATE491707T1 (fr)
AU (1) AU2005243403B2 (fr)
BR (1) BRPI0510762A (fr)
CA (1) CA2564201C (fr)
CR (1) CR8747A (fr)
DE (1) DE602005025345D1 (fr)
DK (1) DK1756104T3 (fr)
EA (1) EA010487B1 (fr)
EC (1) ECSP066984A (fr)
ES (1) ES2355572T3 (fr)
GE (1) GEP20084552B (fr)
GT (1) GT200500112A (fr)
IL (1) IL178882A (fr)
MA (1) MA28579B1 (fr)
MX (1) MXPA06013113A (fr)
NL (1) NL1029016C2 (fr)
NO (1) NO20064577L (fr)
PA (1) PA8632801A1 (fr)
PE (1) PE20060312A1 (fr)
SV (1) SV2005002112A (fr)
TN (1) TNSN06369A1 (fr)
TW (1) TW200607506A (fr)
UY (1) UY28895A1 (fr)
WO (1) WO2005111036A1 (fr)
ZA (1) ZA200609111B (fr)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6468306B1 (en) 1998-05-29 2002-10-22 Advanced Medical Optics, Inc IOL for inhibiting cell growth and reducing glare
WO2005055875A2 (fr) 2003-12-09 2005-06-23 Advanced Medical Optics, Inc. Lentille intraoculaire pliable et procede de fabrication de celle-ci
JP2008543880A (ja) 2005-06-17 2008-12-04 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ナフチリジン化合物
US8158673B2 (en) 2005-10-27 2012-04-17 Pfizer Inc. Histamine-3 receptor antagonists
WO2007052124A1 (fr) * 2005-11-04 2007-05-10 Pfizer Limited Dérivé de tétrahydronaphtyridine
WO2007099423A1 (fr) * 2006-03-02 2007-09-07 Pfizer Products Inc. Dérivés de 1-pyrrolidine indane en tant qu'antagonistes du récepteur d'histamine 3
CA2646023A1 (fr) 2006-03-10 2007-09-20 Neurogen Corporation Piperazinyl-oxoalkyl-tetrahydroisoquinoleines et analogues apparentes
US9108948B2 (en) 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
RU2449989C2 (ru) 2006-06-23 2012-05-10 Эбботт Лэборетриз Производные циклопропиламина в качестве модуляторов h3-гистаминового рецептора
US20100266504A1 (en) * 2007-11-15 2010-10-21 Takahiro Matsumoto Condensed pyridine derivative and use thereof
WO2009082698A1 (fr) * 2007-12-21 2009-07-02 Abbott Laboratories Compositions pour le traitement de troubles cognitifs
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
EP2252613A1 (fr) * 2008-02-22 2010-11-24 Irm, Llc Composés et compositions comme modulateurs d'activité de gpr119
WO2009121812A1 (fr) * 2008-03-31 2009-10-08 Evotec Neurosciences Gmbh Tétrahydronaphthyridines et ses dérivés aza à titre d'antagonistes des récepteurs d'histamine h3
WO2010026113A1 (fr) * 2008-09-03 2010-03-11 Evotec Neurosciences Gmbh Acyl- et sufonyl-tétrahydronaphtyridines et dérivés aza de celles-ci en tant qu’antagonistes de récepteur d’histamine h3
WO2010052222A1 (fr) * 2008-11-07 2010-05-14 Evotec Neurosciences Gmbh Dérivés (dihydro)naphthyridinone comme antagonistes du récepteur h3 de l’histamine
WO2010122064A1 (fr) * 2009-04-21 2010-10-28 Neurosearch A/S Dérivés de naphtyridine substitués et leur utilisation médicale
US9186353B2 (en) 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
US8711772B2 (en) * 2009-05-22 2014-04-29 Qualcomm Incorporated Paging of a user equipment (UE) within a wireless communications system
EP2451281A4 (fr) * 2009-07-09 2013-03-13 Merck Sharp & Dohme Antagonistes des récepteurs à l'orexine à base de tétrahydronaphtyridine
WO2012037258A1 (fr) 2010-09-16 2012-03-22 Abbott Laboratories Procédés de préparation de dérivés cyclopropyliques substitués en 1,2
CN102093356B (zh) * 2011-03-16 2012-12-19 无锡美克赛医药科技有限公司 一种2-氯-5,6,7,8-四氢-1,6-萘啶盐酸盐的制备方法
ES2602794T3 (es) 2011-03-31 2017-02-22 Pfizer Inc Piridinonas bicíclicas novedosas
WO2012172449A1 (fr) 2011-06-13 2012-12-20 Pfizer Inc. Lactames convenant comme inhibiteurs des bêta-sécrétases
JP6043355B2 (ja) 2011-08-31 2016-12-14 ファイザー・インク ヘキサヒドロピラノ［３，４−ｄ］［１，３］チアジン−２−アミン化合物
EP2852597B1 (fr) 2012-05-04 2016-06-08 Pfizer Inc Composés d'hexahydropyrano[3,4-d][1,3]thiazin-2-amine substitués par des hétérocycliques à titre d'inhibiteurs d'app, bace1 et bace2
GEP201706620B (en) 2012-06-29 2017-02-10 Pfizer NOVEL 4-(SUBSTITUTED-AMINO)-7H-PYRROLO[2,3-d]PYRIMIDINES AS LRRK2 INHIBITORS
WO2014045162A1 (fr) 2012-09-20 2014-03-27 Pfizer Inc. Composés d'hexahydropyrano[3,4-d][1,3]thiazine-2-amine alkyl-substitués
UA110688C2 (uk) 2012-09-21 2016-01-25 Пфайзер Інк. Біциклічні піридинони
CA2893256A1 (fr) 2012-12-11 2014-06-19 Pfizer Inc. Composes d'hexahydropyrano [3,4-d][1,3]thiazin-2-amine en tant qu'inhibiteurs de bace1
US9403846B2 (en) 2012-12-19 2016-08-02 Pfizer Inc. Carbocyclic- and heterocyclic-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
WO2014125394A1 (fr) 2013-02-13 2014-08-21 Pfizer Inc. Composés hexahydropyrano [3,4-d][1,3] thiazin-2-amine substitués par un hétéroaryle
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
MA38333A1 (fr) 2013-02-19 2017-02-28 Pfizer Composés d'azabenzimidazole en tant qu'inhibiteurs d'isozymes pde4 pour le traitement de troubles du snc et d'autres affections
MA38559B1 (fr) 2013-05-02 2018-04-30 Pfizer Dérivés d'imidazo-triazine utilisés comme inhibiteurs de la pde10
WO2015049616A1 (fr) 2013-10-04 2015-04-09 Pfizer Inc. Nouvelles pyridinones bicycliques utilisées comme modulateurs de gamma-sécrétase
WO2015092592A1 (fr) 2013-12-17 2015-06-25 Pfizer Inc. Nouvelles 1h-pyrrolo[2,3- b]pyridines 3,4-disubstituées et 7h-pyrrolo[2,3-c]pyridazines 4,5-disubstituées en tant qu'inhibiteurs de la lrrk2
JP6643247B2 (ja) 2014-04-01 2020-02-12 ファイザー・インク ガンマセクレターゼモジュレーターとしてのクロメンおよび１，１ａ，２，７Ｂ−テトラヒドロシクロプロパ［Ｃ］クロメンピリドピラジンジオン
EA030085B1 (ru) 2014-04-10 2018-06-29 Пфайзер Инк. 2-АМИНО-6-МЕТИЛ-4,4a,5,6-ТЕТРАГИДРОПИРАНО[3,4-d][1,3]ТИАЗИН-8a(8H)-ИЛ-1,3-ТИАЗОЛ-4-ИЛ АМИДЫ
WO2016012896A1 (fr) 2014-07-24 2016-01-28 Pfizer Inc. Composés de pyrazolopyrimidine
PT3177624T (pt) 2014-08-06 2019-07-11 Pfizer Compostos de imidazopiridazina
SG11201705780PA (en) 2015-02-03 2017-08-30 Pfizer Novel cyclopropabenzofuranyl pyridopyrazinediones
EP3303348B1 (fr) * 2015-05-28 2019-08-07 Theravance Biopharma R&D IP, LLC Composés de naphthyridine en tant qu'inhibiteurs de kinases jak[
PL3766885T3 (pl) 2015-06-17 2022-09-19 Pfizer Inc. Związki tricykliczne i ich zastosowanie jako inhibitory fosfodiesterazy
EP3350178B1 (fr) 2015-09-14 2021-10-20 Pfizer Inc. Nouveaux dérivés imidazo [4,5-c]quinoline et imidazo [4,5-c][1,5]naphthyridine utilisés comme inhibiteurs de lrrk2
JP2018534251A (ja) 2015-09-24 2018-11-22 ファイザー・インク Ｂａｃｅ阻害剤として有用なｎ−［２−（３−アミノ−２，５−ジメチル−１，１−ジオキシド−５，６−ジヒドロ−２ｈ−１，２，４−チアジアジン−５−イル）−１，３−チアゾール−４−イル］アミド
EP3353182A1 (fr) 2015-09-24 2018-08-01 Pfizer Inc Dérivés de tétrahydropyrano[3,4-d][1,3]oxazine et leur utilisation en tant qu'inhibiteurs de bace
JP2018531923A (ja) 2015-09-24 2018-11-01 ファイザー・インク Ｎ−［２−（２−アミノ−６，６−二置換−４，４ａ，５，６−テトラヒドロピラノ［３，４−ｄ］［１，３］チアジン−８ａ（８Ｈ）−イル）−１，３−チアゾール−４−イル］アミド
US10323042B2 (en) 2016-02-23 2019-06-18 Pfizer Inc. 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
SG11201811712QA (en) 2016-07-01 2019-01-30 Pfizer 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
CA3056027A1 (fr) 2017-03-10 2018-09-13 Pfizer Inc. Derives d'imidazo [4,5-c] quinoleine substitues cycliques
SG11201908322WA (en) 2017-03-10 2019-10-30 Pfizer Novel imidazo[4,5-c]quinoline derivatives as lrrk2 inhibitors
WO2018226992A1 (fr) 2017-06-07 2018-12-13 Adrx, Inc. Inhibiteur d'agrégation de tau
CN110944998B (zh) 2017-06-22 2022-08-16 辉瑞大药厂 二氢-吡咯并-吡啶衍生物
CA3073062A1 (fr) 2017-08-18 2019-02-21 Adrx, Inc. Inhibiteurs peptidiques d'agregation de tau
HUE061533T2 (hu) 2018-03-23 2023-07-28 Pfizer Piperazin azaspiro származékok
US12144815B2 (en) 2021-02-23 2024-11-19 Hoth Therapeutics, Inc. Use of aprepitant for treating Alzheimer's disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
KR0166088B1 (ko) 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
CN1215392A (zh) 1996-02-09 1999-04-28 詹姆斯·布莱克基金有限公司 组胺h3受体配体
WO2000035298A1 (fr) 1996-11-27 2000-06-22 Wm. Wrigley Jr. Company Chewing-gum contenant des agents medicamenteux actifs
GB9711643D0 (en) 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
GB9803536D0 (en) 1998-02-19 1998-04-15 Black James Foundation Histamine H,receptor ligands
EP0982300A3 (fr) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines comme antagonistes du recepteur histamine H3 et leur application thérapeutique
TWI298068B (en) * 2000-06-21 2008-06-21 Dainippon Sumitomo Pharma Co Pharmaceutical composition for schizophrenia
PT1301480E (pt) 2000-07-13 2007-11-29 Abbott Lab Pirrolidinas 1,3-di-substituídas e 1,3,3-tri-substituídas úteis como ligandos do receptor de histamina-3 e suas aplicações terapêuticas
US7186732B2 (en) * 2000-08-08 2007-03-06 Ortho-Mcneil Pharmaceutical, Inc. Non-imidazole aryloxyalkylamines
HUP0302893A3 (en) 2000-08-08 2006-04-28 Ortho Mcneil Pharm Inc Non-imidazole aryloxypiperidines and pharmaceutical compositions containing them and their use
AU2002254114A1 (en) 2001-03-23 2002-10-08 Eli Lilly And Company Non-imidazole aryl alkylamines compounds as histamine h3 receptor antagonists, preparation and therapeutic uses
GB0206033D0 (en) * 2002-03-14 2002-04-24 Pfizer Ltd Compounds useful in therapy
JP4680903B2 (ja) 2003-07-29 2011-05-11 ハイ・ポイント・ファーマスーティカルズ、エルエルシー ピリダジニル−ピペラジンおよびそれらのヒスタミンｈ３受容体リガンドとしての使用
WO2007052124A1 (fr) * 2005-11-04 2007-05-10 Pfizer Limited Dérivé de tétrahydronaphtyridine

Also Published As

Publication number Publication date
GEP20084552B (en) 2008-11-25
US7557121B2 (en) 2009-07-07
AU2005243403B2 (en) 2010-10-07
DK1756104T3 (da) 2011-02-21
AR049092A1 (es) 2006-06-28
CA2564201A1 (fr) 2005-11-24
NL1029016A1 (nl) 2005-11-15
ATE491707T1 (de) 2011-01-15
ZA200609111B (en) 2008-08-27
WO2005111036A1 (fr) 2005-11-24
TW200607506A (en) 2006-03-01
CR8747A (es) 2006-12-05
DE602005025345D1 (de) 2011-01-27
NO20064577L (no) 2006-11-06
IL178882A (en) 2011-03-31
EP1595881A1 (fr) 2005-11-16
US20090258861A1 (en) 2009-10-15
JP2007536374A (ja) 2007-12-13
ES2355572T3 (es) 2011-03-29
AU2005243403A1 (en) 2005-11-24
EP1756104A1 (fr) 2007-02-28
US20050256135A1 (en) 2005-11-17
UY28895A1 (es) 2005-12-30
KR20070014174A (ko) 2007-01-31
CN1950371A (zh) 2007-04-18
AP2006003786A0 (en) 2006-10-31
BRPI0510762A (pt) 2007-11-20
JP4084410B2 (ja) 2008-04-30
EP1756104B1 (fr) 2010-12-15
CA2564201C (fr) 2011-01-18
EA010487B1 (ru) 2008-10-30
IL178882A0 (en) 2007-03-08
ECSP066984A (es) 2006-12-29
GT200500112A (es) 2005-12-12
CN101798305A (zh) 2010-08-11
EA200601897A1 (ru) 2007-02-27
SV2005002112A (es) 2005-12-13
MXPA06013113A (es) 2007-02-28
NL1029016C2 (nl) 2006-05-30
CN1950371B (zh) 2011-01-12
TNSN06369A1 (fr) 2008-02-22
PA8632801A1 (es) 2006-06-02
PE20060312A1 (es) 2006-05-03
KR100908155B1 (ko) 2009-07-16

Similar Documents

Publication Publication Date Title
MA28579B1 (fr) Dérivés de tétrahydronaphtyridine utiles comme ligands du récepteur d'histamine H3
MA28391B1 (fr) Dérivés de 3-cycloalkylaminopyrrolidine utiles comme modulateurs de récepteurs de chimiokines
EP1613961A4 (fr) Complexes de recepteurs de surface utilises comme biomarqueurs
EP1937825A4 (fr) 4'-nucleosides modifies utiles comme agents antiviraux
MA28347A1 (fr) Dérivés de quinoléine substitués
EP2103619A4 (fr) Dérivés d'imidazothiazole
SI1710241T1 (sl) Intermediatne spojine za pripravo trans-5-kloro-2-metil-2,3,3a, 12b-tetrahidro-1H-dibenz(2,3:6,7)oksepino(4,5-C)pirola
MA28798B1 (fr) Dérivés de triazolopyridinylsufanyle servant d'inhibiteurs de kinase MAP P38
MA29037B1 (fr) Derives tetracycliques de l'indole comme agents antiviraux
IL174400A0 (en) Substituted diazabicycloalkane derivatives as ligands at alpha 7 nicotinic acety lcholine receptors
EP1951231A4 (fr) Derives de camptothecine utiles comme agents chimioradiosensibles
EP2096923A4 (fr) Dérivés d'hétéroaryl-amides
ZA200700683B (en) Piperidine derivatives as histamine H3 receptor ligands
ZA200806071B (en) Sulfonyl substituted 1H-indoles as ligands for the 5-hydroxytryptamine receptors
EP2138484A4 (fr) Dérivés d'hétéro-aryle bicyclique fusionnés
SI1802307T1 (sl) Derivati pirolidina kot ligandi histaminskih receptorjev
EP1746141A4 (fr) Composition d' epaississement
EP1810969A4 (fr) Dérivés de benzimidazole aryloxy-substitués
EP1975380A4 (fr) Structure de pot d'échappement pour véhicule
FR2875971B1 (fr) Convertisseur alternatif-continu pour l'aeronautique
DE60305058D1 (de) Imidazoquinoline derivate als adenosine a3 rezeptor liganden
ES2638836T8 (es) Preparación de ED-71
DK1838683T3 (da) Fremgangsmåde til fremstilling af [1,4,5]-oxadiazepinderivater
PL1636223T3 (pl) Pochodne benzotiazolu jako ligandy receptora adenozynowego
NO20034814A (no) Fremgangsmåte for flytting av offshore-konstruksjon